Radically Increasing the Clinical Value of the ECG

“…some of the most significant advances in electrocardiography since its inception, which has historically had a limited, if any, role in the evolution of cardiac dysfunction. In the past, our cardiovascular community was resigned to the fact that surface ECGs are poor indicators for cardiac dysfunction.”

JACC Editorial Commentary
MyoVista Clinical Study – August 2020

Corporate Profile

HeartSciences sits at the forefront of innovation and technological development focused on advancing the field of electrocardiology to provide early heart disease detection. Its first product, the MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device, is a resting 12-lead electrocardiograph that uses AI and continuous wavelet transform (CWT) signal processing to provide cardiac information associated with left ventricular diastolic dysfunction (LVDD), a condition which has previously not been possible to detect using conventional electrocardiology. LVDD is associated with almost all forms and co-morbidities of heart disease and may include hypertension, diabetes, valvular disease, ischemia, and reduced systolic function, among others. The MyoVista Device additionally provides all the information and capabilities of a full-featured conventional resting 12-lead ECG within the same test and follows the same clinical AHA/IEC lead placement protocol. HeartSciences is based in Southlake, Texas. The MyoVista Device is not currently FDA cleared and is not available in the United States.

Price delayed by 15 minutes


Subscribe to our Email Updates to be notified as items are added.

Featured Video

Big Biz Show TV Interview with HeartSciences (HSCS) CEO Andrew Simpson – one of the most significant advances in electrocardiography since its inception

Featured Presentation

Latest Press

Email Sign up

Sign up for email notifications to stay informed of our corporate actions and business progress. Easily unsubscribe at any time.

Stay Updated